Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Japanese Pediatric Patients With Pulmonary Arterial Hypertension
NCT05167825Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Janssen Pharmaceutical. Primary endpoints: Pulmonary Vascular Resistance Index at 24 weeks and Neutrophils Band Form at 52 weeks. Started Nov 2022; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05167825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167825.